Related references
Note: Only part of the references are listed.Coupled regulation by the juxtamembrane and sterile motif (SAM) linker is a hallmark of ephrin tyrosine kinase evolution
Annie Kwon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Structure-Guided Strategy for the Development of Potent Bivalent ERK Inhibitors
Bernhard C. Lechtenberg et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain
Taylor K. Johnson et al.
BIOCONJUGATE CHEMISTRY (2016)
Exquisitely Specific Bisubstrate Inhibitors of c-Src Kinase
Kristoffer R. Brandvold et al.
ACS CHEMICAL BIOLOGY (2015)
Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases
Jing Dong et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Bivalent inhibitors of protein kinases
Carrie M. Gower et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Pyrrolo[3,2-b]quinoxaline Derivatives as Types I1/2 and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation
Andrea Unzue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Optimization of Inhibitors of the Tyrosine Kinase EphB4. 2. Cellular Potency Improvement and Binding Mode Validation by X-ray Crystallography
Karine Lafleur et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Development of a Highly Selective c-Src Kinase Inhibitor
Kristoffer R. Brandvold et al.
ACS CHEMICAL BIOLOGY (2012)
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Vandana Lamba et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis
Nirmitha I. Herath et al.
EUROPEAN JOURNAL OF CANCER (2012)
Discovery of a Novel Chemotype of Tyrosine Kinase Inhibitors by Fragment-Based Docking and Molecular Dynamics
Hongtao Zhao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Development of Homomultimers and Heteromultimers of Lung Cancer-Specific Peptoids
Jared C. Hooks et al.
BIOPOLYMERS (2011)
A Semisynthetic Eph Receptor Tyrosine Kinase Provides Insight into Ligand-Induced Kinase Activation
Nikhil Singla et al.
CHEMISTRY & BIOLOGY (2011)
Design and Characterization of a Potent and Selective Dual ATP- and Substrate-Competitive Subnanomolar Bidentate c-Jun N-Terminal Kinase (JNK) Inhibitor
John L. Stebbins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Bisubstrate Inhibitors of Protein Kinases: from Principle to Practical Applications
Darja Lavogina et al.
CHEMMEDCHEM (2010)
Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State
Neal K. Williams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3)
Tara L. Davis et al.
STRUCTURE (2008)
Tethering small molecules to a phage display library: Discovery of a selective bivalent inhibitor of protein kinase A
Scott C. Meyer et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Identification of a peptoid inhibitor of the proteasome 19S regulatory particle
Hyun-Suk Lim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines
BP Fox et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Increasing the kinase specificity of K252a by protein surface recognition
TL Schneider et al.
ORGANIC LETTERS (2005)
Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A
AC Hines et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Conversion of a tyrosine kinase protein substrate to a high affinity ligand by ATP linkage
K Shen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Microwave-assisted solid-phase synthesis of peptoids
HJ Olivos et al.
ORGANIC LETTERS (2002)
Designing bisubstrate analog inhibitors for protein kinases
K Parang et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses
AH Zisch et al.
ONCOGENE (2000)
Share Paper
